Overview

Corporate Profile

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today. The T2Sepsis SolutionTM is a unique approach that combines the standard of care for the management of sepsis patients with T2 Biosystems’ products, including the T2Dx® Instrument and T2Candida® Panel, and the T2Bacteria® Panel, which is commercially available in Europe and other countries that accept the CE Mark and available for research use only in the U.S. Powered by the proprietary T2 Magnetic Resonance technology, or T2MR®, the T2Sepsis Solution is proven to deliver better patient care and greater cost savings. Hospital customer experience has demonstrated faster time to effective treatment, shortened ICU and hospital lengths of stay, reduced use of unnecessary antifungals, and millions of dollars in savings. T2 Biosystems has an active pipeline of future sepsis products including additional species and antibiotic resistance, as well as tests for Lyme disease and hemostasis. For more information, please visit  www.t2biosystems.com.
Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$8.77
Change (%) Stock is Up 0.24 (2.81%)
Volume488,686
Data as of 05/22/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
05/08/18T2 Biosystems Reports First Quarter 2018 Financial Results and Provides Corporate Update
Quarterly Product Revenue Up 66% Year-Over-Year On Track for Potential FDA Clearance of T2Bacteria Panel in the Second Quarter 2018 LEXINGTON, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today operating highlights and financial results for the first quarter ended March 31, 2018.   First Quarter Business and Fi... 
Printer Friendly Version
05/03/18T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on May 1, 2018 it issued inducement awards to four new employees.    These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides fo... 
Printer Friendly Version
04/30/18T2 Biosystems Announces 2018 First Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2018 first quarter financial and operational results after the market closes on Tuesday, May 8, 2018. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern T... 
Printer Friendly Version
04/04/18T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on April 2, 2018 it issued inducement awards to five new employees.    These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646

Matthew Clawson, W2O Group 
mclawson@w2ogroup.com
(339) 370-8500

Data provided by Nasdaq. Minimum 15 minutes delayed.